Chimeric antigen receptor T-cell therapy for solid tumors

Molecular Therapy - Oncolytics

Volumn 3, Issue , 2016, Pages

  Newick, Kheng ^a   Moon, Edmund ^a   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; CELL MIGRATION; CELL THERAPY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 85044231668     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1038/mto.2016.6     Document Type: Review

References (75)

1. Topalian, SL, Drake, CG and Pardoll, DM (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27: 450-461.
2. Willemsen, RA, Debets, R, Hart, E, Hoogenboom, HR, Bolhuis, RL and Chames, P (2001). A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther 8: 1601-1608.
3. Gill, S, Maus, MV and Porter, DL (2015). Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev (Epub ahead of print).
4. Fousek, K and Ahmed, N (2015). The evolution of T-cell therapies for solid malignancies. Clin Cancer Res 21: 3384-3392.
5. Louis, CU, Savoldo, B, Dotti, G, Pule, M, Yvon, E, Myers, GD et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118: 6050-6056.
6. Ahmed, N, Brawley, VS, Hegde, M, Robertson, C, Ghazi, A, Gerken, C et al. (2015). Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33: 1688-1696.
7. Restifo, NP, Dudley, ME and Rosenberg, SA (2012). Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-281.
8. Johnson, LA, Scholler, J, Ohkuri, T, Kosaka, A, Patel, PR, McGettigan, SE et al. (2015). Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 7: 275ra22.
9. Morgan, RA, Johnson, LA, Davis, JL, Zheng, Z, Woolard, KD, Reap, EA et al. (2012). Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 23: 1043-1053.
10. Wilkie, S, Picco, G, Foster, J, Davies, DM, Julien, S, Cooper, L et al. (2008). Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 180: 4901-4909.
11. Chekmasova, AA, Rao, TD, Nikhamin, Y, Park, KJ, Levine, DA, Spriggs, DR et al. (2010). Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res 16: 3594-3606.
12. Chmielewski, M, Hahn, O, Rappl, G, Nowak, M, Schmidt-Wolf, IH, Hombach, AA et al. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 143: 1095-107.e2.
13. Parkhurst, MR, Yang, JC, Langan, RC, Dudley, ME, Nathan, DA, Feldman, SA et al. (2011). T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19: 620-626.
14. Kenter, GG, Welters, MJ, Valentijn, AR, Lowik, MJ, Berends-van der Meer, DM, Vloon, AP et al. (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361: 1838-1847.
15. Morello, A, Sadelain, M and Adusumilli, PS (2016). Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 6: 133-146.
16. Pastan, I and Hassan, R (2014). Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 74: 2907-2912.
17. Chowdhury, PS, Viner, JL, Beers, R and Pastan, I (1998). Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA 95: 669-674.
18. Lanitis, E, Poussin, M, Hagemann, IS, Coukos, G, Sandaltzopoulos, R, Scholler, N et al. (2012). Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther 20: 633-643.
19. Adusumilli, PS, Cherkassky, L, Villena-Vargas, J, Colovos, C, Servais, E, Plotkin, J et al. (2014). Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 6: 261ra151.
20. Wilkie, S, van Schalkwyk, MC, Hobbs, S, Davies, DM, van der Stegen, SJ, Pereira, AC et al. (2012). Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32: 1059-1070.
21. Wang, LC, Lo, A, Scholler, J, Sun, J, Majumdar, RS, Kapoor, V et al. (2014). Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2: 154-166.
22. Chinnasamy, D, Tran, E, Yu, Z, Morgan, RA, Restifo, NP and Rosenberg, SA (2013). Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res 73: 3371-3380.
23. Harlin, H, Meng, Y, Peterson, AC, Zha, Y, Tretiakova, M, Slingluff, C et al. (2009). Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69: 3077-3085.
24. Moon, EK, Carpenito, C, Sun, J, Wang, LC, Kapoor, V, Predina, J et al. (2011). Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17: 4719-4730.
25. Craddock, JA, Lu, A, Bear, A, Pule, M, Brenner, MK, Rooney, CM et al. (2010). Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33: 780-788.
26. Newick, K, O'Brien, S, Sun, J, Kapoor, V, Maceyko, S, Lo, A et al. (2016). Augmentation of CAR T cell trafficking and antitumor efficact by blocking protein kinase A (PKA) localization. Cancer Immunol Res. In press.
27. Nishio, N, Diaconu, I, Liu, H, Cerullo, V, Caruana, I, Hoyos, V et al. (2014). Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res 74: 5195-5205.
28. VanSeggelen, H, Hammill, JA, Dvorkin-Gheva, A, Tantalo, DG, Kwiecien, JM, Denisova, GF et al. (2015). T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Mol Ther 23: 1600-1610.
29. Caruana, I, Savoldo, B, Hoyos, V, Weber, G, Liu, H, Kim, ES et al. (2015). Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21: 524-529.
30. Jacobs, SR, Herman, CE, Maciver, NJ, Wofford, JA, Wieman, HL, Hammen, JJ et al. (2008). Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol 180: 4476-4486.
31. Fischer, K, Hoffmann, P, Voelkl, S, Meidenbauer, N, Ammer, J, Edinger, M et al. (2007). Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109: 3812-3819.
32. Howie, D, Waldmann, H and Cobbold, S (2014). Nutrient sensing via mTOR in T cells maintains a tolerogenic microenvironment. Front Immunol 5: 409.
33. Ninomiya, S, Narala, N, Huye, L, Yagyu, S, Savoldo, B, Dotti, G et al. (2015). Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125: 3905-3916.
34. Veliça, P, Zech, M, Henson, S, Holler, A, Manzo, T, Pike, R et al. (2015). Genetic regulation of fate decisions in therapeutic T cells to enhance tumor protection and memory formation. Cancer Res 75: 2641-2652.
35. Sukumar, M, Liu, J, Ji, Y, Subramanian, M, Crompton, JG, Yu, Z et al. (2013). Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 123: 4479-4488.
36. Goodwin, JS, Bankhurst, AD and Messner, RP (1977). Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med 146: 1719-1734.
37. Su, Y, Huang, X, Raskovalova, T, Zacharia, L, Lokshin, A, Jackson, E et al. (2008). Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother 57: 1611-1623.
38. Oh, SA and Li, MO (2013). TGF-β: guardian of T cell function. J Immunol 191: 3973-3979.
39. Massagué, J (2008). TGFbeta in Cancer. Cell 134: 215-230.
40. Wallace, A, Kapoor, V, Sun, J, Mrass, P, Weninger, W, Heitjan, DF et al. (2008). Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 14: 3966-3974.
41. Bollard, CM, Rössig, C, Calonge, MJ, Huls, MH, Wagner, HJ, Massague, J et al. (2002). Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99: 3179-3187.
42. Leen, AM, Sukumaran, S, Watanabe, N, Mohammed, S, Keirnan, J, Yanagisawa, R et al. (2014). Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther 22: 1211-1220.
43. Wilkie, S, Burbridge, SE, Chiapero-Stanke, L, Pereira, AC, Cleary, S, van der Stegen, SJ et al. (2010). Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 285: 25538-25544.
44. Chmielewski, M, Hombach, AA and Abken, H (2014). Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257: 83-90.
45. Zhang, L, Morgan, RA, Beane, JD, Zheng, Z, Dudley, ME, Kassim, SH et al. (2015). Tumorinfiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 21: 2278-2288.
46. Gabrilovich, DI and Nagaraj, S (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
47. Mussai, F, Egan, S, Hunter, S, Webber, H, Fisher, J, Wheat, R et al. (2015). Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. Cancer Res 75: 3043-3053.
48. Burga, RA, Thorn, M, Point, GR, Guha, P, Nguyen, CT, Licata, LA et al. (2015). Liver myeloidderived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother 64: 817-829.
49. Spear, P, Barber, A, Rynda-Apple, A and Sentman, CL (2012). Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-? and GM-CSF. J Immunol 188: 6389-6398.
50. Sakaguchi, S, Miyara, M, Costantino, CM and Hafler, DA (2010). FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10: 490-500.
51. Zhou, Q, Munger, ME, Highfill, SL, Tolar, J, Weigel, BJ, Riddle, M et al. (2010). Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 116: 2484-2493.
52. Liu, Y, Wang, L, Predina, J, Han, R, Beier, UH, Wang, LC et al. (2013). Inhibition of p300 impairs Foxp3? T regulatory cell function and promotes antitumor immunity. Nat Med 19: 1173-1177.
53. Perna, SK, Pagliara, D, Mahendravada, A, Liu, H, Brenner, MK, Savoldo, B et al. (2014). Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 20: 131-139.
54. Yao, X, Ahmadzadeh, M, Lu, YC, Liewehr, DJ, Dudley, ME, Liu, F et al. (2012). Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119: 5688-5696.
55. Kofler, DM, Chmielewski, M, Rappl, G, Hombach, A, Riet, T, Schmidt, A et al. (2011). CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation. Mol Ther 19: 760-767.
56. Markley, JC and Sadelain, M (2010). IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115: 3508-3519.
57. Finney, HM, Akbar, AN and Lawson, AD (2004). Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172: 104-113.
58. Moon, EK, Wang, LC, Dolfi, DV, Wilson, CB, Ranganathan, R, Sun, J et al. (2014). Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptortransduced human T cells in solid tumors. Clin Cancer Res 20: 4262-4273.
59. John, LB, Devaud, C, Duong, CP, Yong, CS, Beavis, PA, Haynes, NM et al. (2013). Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by genemodified T cells. Clin Cancer Res 19: 5636-5646.
60. Moon, EK, Ranganathan, R, Eruslanov, E, Kim, S, Newick, K, O'Brien, S et al. (2016). Blockade of programmed death 1 augments the ability of human T cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer. Clin Cancer Res 22: 436-447.
61. Kobold, S, Grassmann, S, Chaloupka, M, Lampert, C, Wenk, S, Kraus, F et al. (2015). Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J Natl Cancer Inst 107:djv146 .
62. Mahvi, DA, Meyers, JV, Tatar, AJ, Contreras, A, Suresh, M, Leverson, GE et al. (2015). Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice. J Immunother 38: 54-61.
63. Wang, LC, Riese, MJ, Moon, EK and Albelda, SM (2013). Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road. Oncoimmunology 2: e26492.
64. Riese, MJ, Wang, LC, Moon, EK, Joshi, RP, Ranganathan, A, June, CH et al. (2013). Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res 73: 3566-3577.
65. Charo, J, Finkelstein, SE, Grewal, N, Restifo, NP, Robbins, PF and Rosenberg, SA (2005). Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res 65: 2001-2008.
66. Ramos, CA, Savoldo, B and Dotti, G (2014). CD19-CAR trials. Cancer J 20: 112-118.
67. Lee, DW, Gardner, R, Porter, DL, Louis, CU, Ahmed, N, Jensen, M et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124: 188-195.
68. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM and Rosenberg, SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
69. Lanitis, E, Poussin, M, Klattenhoff, AW, Song, D, Sandaltzopoulos, R, June, CH et al. (2013). Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 1: 43-53.
70. Kloss, CC, Condomines, M, Cartellieri, M, Bachmann, M and Sadelain, M (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31: 71-75.
71. Tey, SK, Dotti, G, Rooney, CM, Heslop, HE and Brenner, MK (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13: 913-924.
72. Beatty, GL, Haas, AR, Maus, MV, Torigian, DA, Soulen, MC, Plesa, G et al. (2014). Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res 2: 112-120.
73. Guedan, S, Chen, X, Madar, A, Carpenito, C, McGettigan, SE, Frigault, MJ et al. (2014). ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 124: 1070-1080.
74. Song, DG, Ye, Q, Poussin, M, Harms, GM, Figini, M and Powell, DJ Jr (2012). CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119: 696-706.
75. Wang, E, Wang, LC, Tsai, CY, Bhoj, V, Gershenson, Z, Moon, E et al. (2015). Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors. Cancer Immunol Res 3: 815-826